Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Inhibikase Therapeutics’ SEC disclosures can feel like wading through dense clinical jargon and trial acronyms. Each 10-K details kinase-inhibitor chemistry, while a single 8-K may unveil pivotal Phase 2a data that moves the stock overnight. If you have ever searched “Inhibikase Therapeutics SEC filings explained simply” or wondered how to track “Inhibikase Therapeutics insider trading Form 4 transactions,” you already know the challenge.
Stock Titan solves it. Our AI reads every Inhibikase Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events explained line by line, then delivers plain-English takeaways—trial milestones, dilution risk and cash runway—in seconds. Real-time alerts flag “Inhibikase Therapeutics Form 4 insider transactions real-time,” so you see executive stock transactions Form 4 the moment they hit EDGAR. Need proxy details? We map “Inhibikase Therapeutics proxy statement executive compensation” into clear tables, and our engine links each metric to historical context.
Here’s what professionals monitor on our platform:
- Pipeline progress buried in 10-Q footnotes—converted to concise bullets
- Risk-factor shifts after FDA feedback, surfaced from 8-K filings
- Cash burn trends with “Inhibikase Therapeutics earnings report filing analysis” ready for comparison
- “Understanding Inhibikase Therapeutics SEC documents with AI” through interactive summaries
Whether you follow “Inhibikase Therapeutics quarterly earnings report 10-Q filing” for R&D spend or track “Inhibikase Therapeutics 8-K material events explained” ahead of a catalyst, our comprehensive filing coverage and expert AI put critical biotech insights one click away.
Form 4 filing – Inhibikase Therapeutics, Inc. (IKT)
On 06/30/2025, director Dennis N. Berman received 108,176 stock options with an exercise price of $1.95 per share. The grant vests on the earlier of 06/30/2026 or the day prior to the company’s next annual shareholder meeting, subject to continued board service, and expires on 06/30/2032. No common shares were bought or sold in this filing; the reporting person’s beneficial ownership now includes the newly issued options, held directly.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
